AZD9550

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Weight LossHepatic ImpairmentObesity & OverweightOverweight and Obesity

35 competitors in Weight Loss

#DrugCompanyPhaseTrials

1

Victoza

Novo Nordisk

Approved

132

Ozempic

Novo Nordisk

Approved

103

Farxiga

AstraZeneca

Approved

44

Glucophage

EMD Serono

Approved

85

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Approved

76

Topamax

WWim Janssens

Approved

37

Invokana

WWim Janssens

Approved

28

Xifaxan

SSalix

Approved

29

Megace

Bristol-Myers Squibb

Phase 3

1010

Versed

CConrado Roberto Hoffmann Filho

Approved

1Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Weight loss1 trial

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Active, not recruiting·AstraZeneca·Phase 2·NCT06862791·377 enrolled

Single Ascending Dose1 trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Completed·AstraZeneca·Phase 1·NCT05848440·48 enrolled

Hepatic Impairment1 trial

A Phase I, Multicentre, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD9550 and AZD6234

Recruiting·AstraZeneca·Phase 1·NCT07546760·28 enrolled

Overweight and Obesity1 trial

A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 Monotherapy and Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity and Overweight With or Without Type 2 Diabetes Mellitus

Active, not recruiting·AstraZeneca·Preclinical·NCT06151964·166 enrolled

Obesity & Overweight1 trial

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

Active, not recruiting·AstraZeneca·Phase 2·NCT07017179·14 enrolled

1 more indication

Unspecified1 trial

An Open-label, Single-sequence Multiple Cohort Study to Assess the Effect of Multiple Doses of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on the Pharmacokinetics of Single Doses of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Recruiting·AstraZeneca·Phase 1·NCT07013643·50 enrolled

Details

Drug Info

Related News